Eli Lilly and Company (India) Pvt. Ltd. (Lilly) and Cipla Limited (BOM: 500087, NSE: CIPLA) today announced a strategic distribution agreement for Lilly’s second tirzepatide product, Yurpeak, in India. The deal expands market access beyond the limited geographic footprint where Lilly has already launched its flagship tirzepatide, Mounjaro.
Key Terms of the Agreement
- Distribution Rights – Cipla will obtain exclusive rights to distribute and promote Yurpeak across India.
- Manufacturing & Supply – Lilly will manufacture and supply the product to Cipla under the same pricing structure as Mounjaro.
- Commercial Scope – The partnership aims to broaden availability of tirzepatide nationwide, reaching patients outside major urban centers.
Product Profile – Yurpeak
- Active Ingredient – Tirzepatide, a dual agonist of GIP and GLP‑1 receptors.
- Indications – Adjunct to diet and exercise for type 2 diabetes; chronic weight management in adults with BMI ≥ 27 (overweight) or ≥ 30 (obese) plus at least one weight‑related comorbidity.
- Formulation – KwikPen pre‑filled pen, multi‑dose single‑patient use, 4 fixed doses per pen.
- Dosing – Once weekly, six strength options: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg.
Strategic Impact
- Expanded Reach – Cipla’s extensive distribution network will enable Yurpeak to reach underserved regions, enhancing treatment access for diabetes and obesity patients.
- Competitive Positioning – By offering a second tirzepatide product at the same price point, Lilly reinforces its leadership in the emerging dual‑agonist market.
- Collaborative Synergy – The partnership leverages Lilly’s clinical expertise and Cipla’s local market knowledge, promising a streamlined go‑to‑market strategy.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech
